Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Detection of characteristic metabolites of Aspergillus fumigatus and Candida species using ion mobility spectrometry-metabolic profiling by volatile organic compounds.

Perl T, Jünger M, Vautz W, Nolte J, Kuhns M, Borg-von Zepelin M, Quintel M.

Mycoses. 2011 Nov;54(6):e828-37. doi: 10.1111/j.1439-0507.2011.02037.x. Epub 2011 Jun 12.

PMID:
21668516
2.

Difference in virulence between fluconazole-susceptible and fluconazole-resistant Candida albicans in a mouse model.

Schulz B, Weber K, Schmidt A, Borg-von Zepelin M, Ruhnke M.

Mycoses. 2011 Sep;54(5):e522-30. doi: 10.1111/j.1439-0507.2010.01970.x. Epub 2011 May 23.

PMID:
21605180
3.

Two serial check valves can prevent cross-contamination through intravenous tubing during total intravenous anesthesia.

Radke OC, Werth K, Borg-von-Zepelin M, Saur P, Apfel CC.

Anesth Analg. 2010 Oct;111(4):925-8. doi: 10.1213/ANE.0b013e3181eb7194. Epub 2010 Sep 1.

PMID:
20810677
4.

Decontamination efficacy of antiseptic agents on in vivo grown biofilms on rough titanium surfaces.

Sennhenn-Kirchner S, Wolff N, Klaue S, Mergeryan H, Borg-von Zepelin M.

Quintessence Int. 2009 Nov-Dec;40(10):e80-8.

PMID:
19898707
5.

Dental therapy before and after radiotherapy--an evaluation on patients with head and neck malignancies.

Sennhenn-Kirchner S, Freund F, Grundmann S, Martin A, Borg-von Zepelin M, Christiansen H, Wolff HA, Jacobs HG.

Clin Oral Investig. 2009 Jun;13(2):157-64. doi: 10.1007/s00784-008-0229-1. Epub 2008 Oct 17.

6.

[The epidemiology of Candida infections in Göttingen and Germany].

Borg-von Zepelin M.

Mycoses. 2008 Sep;51 Suppl 3:17-9. doi: 10.1111/j.1439-0507.2008.01580.x. German. No abstract available.

PMID:
18782238
7.

Decontamination efficacy of erbium:yttrium-aluminium-garnet and diode laser light on oral Candida albicans isolates of a 5-day in vitro biofilm model.

Sennhenn-Kirchner S, Schwarz P, Schliephake H, Konietschke F, Brunner E, Borg-von Zepelin M.

Lasers Med Sci. 2009 May;24(3):313-20. doi: 10.1007/s10103-008-0561-3. Epub 2008 May 6.

8.

Basidiomycete metabolites attenuate virulence properties of Candida albicans in vitro.

Falkensammer B, Pleyer L, Ressler S, Berg A, Borg-von Zepelin M, Nagl M, Lass-Flörl C, Speth C, Dierich MP, Würzner R.

Mycoses. 2008 Nov;51(6):505-14. doi: 10.1111/j.1439-0507.2008.01515.x. Epub 2008 Apr 16.

9.

Preoperative sterilization and disinfection of drill guide templates.

Sennhenn-Kirchner S, Weustermann S, Mergeryan H, Jacobs HG, Borg-von Zepelin M, Kirchner B.

Clin Oral Investig. 2008 Jun;12(2):179-87. Epub 2007 Oct 5.

PMID:
17917747
10.

Epidemiology and antifungal susceptibilities of Candida spp. to six antifungal agents: results from a surveillance study on fungaemia in Germany from July 2004 to August 2005.

Borg-von Zepelin M, Kunz L, Rüchel R, Reichard U, Weig M, Gross U.

J Antimicrob Chemother. 2007 Aug;60(2):424-8. Epub 2007 Jun 11.

PMID:
17562683
11.

Decontamination of rough titanium surfaces with diode lasers: microbiological findings on in vivo grown biofilms.

Sennhenn-Kirchner S, Klaue S, Wolff N, Mergeryan H, Borg von Zepelin M, Jacobs HG.

Clin Oral Implants Res. 2007 Feb;18(1):126-32.

PMID:
17224033
12.

[What happens in fungal infections at the molecular level? Fungal pathogens].

Borg-von Zepelin M, Monod M.

Pharm Unserer Zeit. 2003;32(2):110-6. Review. German. No abstract available.

PMID:
12677963
13.

Effect of Micafungin (FK463) on Candida albicans adherence to epithelial cells.

Borg-von Zepelin M, Zaschke K, Gross U, Monod M, Müller FM.

Chemotherapy. 2002 Jul;48(3):148-53.

PMID:
12138332
14.

Secreted proteinases and other virulence mechanisms of Candida albicans.

Monod M, Borg-von Zepelin M.

Chem Immunol. 2002;81:114-28. Review. No abstract available.

PMID:
12101999
15.

Adherence of different Candida dubliniensis isolates in the presence of fluconazole.

Borg-von Zepelin M, Niederhaus T, Gross U, Seibold M, Monod M, Tintelnot K.

AIDS. 2002 Jun 14;16(9):1237-44.

PMID:
12045488
16.

Impact of N-chlorotaurine on viability and production of secreted aspartyl proteinases of Candida spp.

Nagl M, Gruber A, Fuchs A, Lell CP, Lemberger EM, Borg-Von Zepelin M, Würzner R.

Antimicrob Agents Chemother. 2002 Jun;46(6):1996-9.

17.

Peptides that mimic Candida albicans-derived beta-1,2-linked mannosides.

Jouault T, Fradin C, Dzierszinski F, Borg-Von-Zepelin M, Tomavo S, Corman R, Trinel PA, Kerckaert JP, Poulain D.

Glycobiology. 2001 Aug;11(8):693-701.

PMID:
11479280
18.

HIV protease inhibitors attenuate adherence of Candida albicans to epithelial cells in vitro.

Bektić J, Lell CP, Fuchs A, Stoiber H, Speth C, Lass-Flörl C, Borg-von Zepelin M, Dierich MP, Würzner R.

FEMS Immunol Med Microbiol. 2001 Jul;31(1):65-71.

19.

Secreted aspartic proteinase family of Candida tropicalis.

Zaugg C, Borg-Von Zepelin M, Reichard U, Sanglard D, Monod M.

Infect Immun. 2001 Jan;69(1):405-12.

20.

HIV-Protease inhibitors reduce cell adherence of Candida albicans strains by inhibition of yeast secreted aspartic proteases.

Borg-von Zepelin M, Meyer I, Thomssen R, Würzner R, Sanglard D, Telenti A, Monod M.

J Invest Dermatol. 1999 Nov;113(5):747-51.

21.

Dissimilar attenuation of Candida albicans virulence properties by human immunodeficiency virus type 1 protease inhibitors.

Gruber A, Berlit J, Speth C, Lass-Flörl C, Kofler G, Nagl M, Borg-von Zepelin M, Dierich MP, Würzner R.

Immunobiology. 1999 Sep;201(1):133-44.

PMID:
10532286
22.

The inhibition of Candida-albicans-secreted aspartic proteases by three different HIV protease inhibitors.

Monod M, Borg-von Zepelin M, Telenti A, Sanglard D.

Dermatology. 1999;198(4):412-4. No abstract available.

PMID:
10490300
23.

Human immunodeficiency virus type 1 protease inhibitor attenuates Candida albicans virulence properties in vitro.

Gruber A, Speth C, Lukasser-Vogl E, Zangerle R, Borg-von Zepelin M, Dierich MP, Würzner R.

Immunopharmacology. 1999 Apr;41(3):227-34.

PMID:
10428651
24.

In vivo expression and localization of Candida albicans secreted aspartyl proteinases during oral candidiasis in HIV-infected patients.

Schaller M, Hube B, Ollert MW, Schäfer W, Borg-von Zepelin M, Thoma-Greber E, Korting HC.

J Invest Dermatol. 1999 Mar;112(3):383-6.

25.

The expression of the secreted aspartyl proteinases Sap4 to Sap6 from Candida albicans in murine macrophages.

Borg-von Zepelin M, Beggah S, Boggian K, Sanglard D, Monod M.

Mol Microbiol. 1998 May;28(3):543-54.

26.

Human immunodeficiency virus type 1 gp160 and gp41 binding to Candida albicans selectively enhances candidal virulence in vitro.

Gruber A, Lukasser-Vogl E, Borg-von Zepelin M, Dierich MP, Würzner R.

J Infect Dis. 1998 Apr;177(4):1057-63.

PMID:
9534982
27.

[Involvement of secretory Candida proteinases in the adherence of C. tropicalis blastoconidia in a cell culture model].

Borg-von Zepelin M, Eucker J, Rüchel R.

Mycoses. 1997;40 Suppl 1:64-72. German.

PMID:
9417516
28.

Increased expression of Candida albicans secretory proteinase, a putative virulence factor, in isolates from human immunodeficiency virus-positive patients.

Ollert MW, Wende C, Görlich M, McMullan-Vogel CG, Borg-von Zepelin M, Vogel CW, Korting HC.

J Clin Microbiol. 1995 Oct;33(10):2543-9.

29.

Fluorescence assay for the detection of adherent Candida yeasts to target cells in microtest plates.

Borg-von Zepelin M, Wagner T.

Mycoses. 1995 Sep-Oct;38(9-10):339-47.

PMID:
8569807
30.

pH-dependent denaturation of extracellular aspartic proteinases from Candida species.

Wagner T, Borg von Zepelin M, Rüchel R.

J Med Vet Mycol. 1995 Jul-Aug;33(4):275-8.

PMID:
8531028
31.
33.
34.

Chemiluminescence of polymorphonuclear granulocytes in the presence of selected Candida species.

Borg-von Zepelin M, Schuff-Werner P.

Mycoses. 1992 May-Jun;35(5-6):121-9.

PMID:
1474983
35.

Bacteria accompanying clinical Candida isolates from respiratory secretions and the genitourinary tract.

Rüchel R, Borg-von Zepelin M, Eiffert H, Muche R.

Mycoses. 1991 May-Jun;34(5-6):235-8.

PMID:
1795719

Supplemental Content

Loading ...
Support Center